MedTrace Logo

Study to Evaluate the Immunogenicity and Safety of 'IL-YANG Quadrivalent Influenza Vaccine Inj.'

NCT02677493 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1794

Last updated 2023-09-28

Study results available
· View outcomes & findings →

Summary

This study evaluates the immunogenicity and safety of 'IL-YANG Quadrivalent Influenza Vaccine Inj.' in healthy male and female adults at the age of 19 or older.

Conditions

Interventions

BIOLOGICAL

IL-YANG Quadrivalent Influenza Vaccine

A single 0.5mL dose administrated as an intramuscular injection.

BIOLOGICAL

IL-YANG Flu Vaccine Prefilled Syringe

A single 0.5mL dose administrated as an intramuscular injection.

BIOLOGICAL

IL-YANG Trivalent Influenza Vaccine

A single 0.5mL dose administrated as an intramuscular injection.

Sponsors & Collaborators

  • Il-Yang Pharm. Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2016-01-31
Completion
2016-06-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02677493 on ClinicalTrials.gov